ClinicalTrials.gg
CompletedNCT02815644Updated Aug 16, 2018Results posted

Empa/Lina FDC Food Effect Study (Japan)

A Phase 1 interventional study of empagliflozin/linagliptin FDC in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Japan. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-16.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Male
01

Study summary

The trial will be performed as an open-label, randomised, single-dose, two-sequence crossover design for the assessment of effect of food on bioavailability of empagliflozin / linagliptin fixed dose combination (FDC) tablet.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects age >=20 and \<=45 years; body weight: >=50 kg and \<=80 kg; : >=18.0 and \<=25.0 kg/m2
  • Without any findings and complications on the basis of a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR), body temperature)
  • Signed and dated written prior to admission to the trial in accordance with the Good Clinical Practice (GCP) and the local legislation

Exclusion criteria

Exclusion criteria:

  • Any finding of the medical examination (including blood pressure, pulse rate and ) deviating from normal and of clinical relevance
  • Further exclusion criteria apply
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    empagliflozin/linagliptin FDC

    empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet

    Drug: empagliflozin/linagliptin FDC

Interventions

  • Drugempagliflozin/linagliptin FDC

    Drug pages: Empagliflozin · Linagliptin

    empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet

06

What researchers measure

Primary outcomes

  1. Cmax for Linagliptin

    Maximum measured concentration of the analyte in plasma (Cmax) for linagliptin

    Time frame: 2 hours (h) before the administration in first subject and 0:20 h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, 72:00h after drug administration.

  2. Cmax for Empagliflozin

    Maximum measured concentration of the analyte in plasma (Cmax) for empagliflozin

    Time frame: 2 hours (h) before the administration in first subject and 0:20 h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, 72:00h after drug administration.

  3. AUC 0-tz for Linagliptin

    Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration (AUC 0-tz) for linagliptin

    Time frame: 2 hours (h) before the administration in first subject and 0:20 h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, 72:00h after drug administration.

  4. AUC 0-tz for Empagliflozin

    Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration (AUC 0-tz) for empagliflozin

    Time frame: 2 hours (h) before the administration in first subject and 0:20 h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, 72:00h after drug administration.

Secondary outcomes

  1. AUC0-infinity for Linagliptin

    Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-infinity) for linagliptin

    Time frame: 2 hours (h) before the administration in first subject and 0:20 h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, 72:00h after drug administration.

  2. AUC0-infinity for Empagliflozin

    Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-infinity) for empagliflozin.

    Time frame: 2 hours (h) before the administration in first subject and 0:20 h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, 72:00h after drug administration.

  3. AUC0-72 for Linagliptin

    Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 72 hours (AUC0-72) for linagliptin

    Time frame: 2 hours (h) before the administration in first subject and 0:20 h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, 72:00h after drug administration.

07

Results

Posted Aug 16, 2018

Participant flow

Treatment Period 1 + Washout
Participant flow — Treatment Period 1 + Washout
MilestoneEmpagliflozin 25 mg/ Linagliptin 5 mg (Sequence 1: Fed-Fasted)Empagliflozin 25 mg/ Linagliptin 5 mg (Sequence 2: Fasted-Fed)
Started1111
Completed1111
Not completed00
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneEmpagliflozin 25 mg/ Linagliptin 5 mg (Sequence 1: Fed-Fasted)Empagliflozin 25 mg/ Linagliptin 5 mg (Sequence 2: Fasted-Fed)
Started1111
Completed1111
Not completed00

Outcome measures

PrimaryCmax for Linagliptin

Maximum measured concentration of the analyte in plasma (Cmax) for linagliptin

Time frame:
2 hours (h) before the administration in first subject and 0:20 h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, 72:00h after drug administration.
Reported as:
Geometric mean · nmol/L
Cmax for Linagliptin
nmol/LEmpagliflozin 25 mg/ Linagliptin 5 mg (Reference;Fasted)Empagliflozin 25 mg/ Linagliptin 5 mg (Test;Fed)
Cmax for Linagliptin15.1 ± 50.68.43 ± 30.3
Statistical analysis
  • Empagliflozin 25 mg/ Linagliptin 5 mg (Reference;Fasted) vs Empagliflozin 25 mg/ Linagliptin 5 mg (Test;Fed) · T/r ratio: 55.69 · 90% CI 48.22 to 64.33Standard Error of the mean is actually geometric Standard Error of the mean.
PrimaryCmax for Empagliflozin

Maximum measured concentration of the analyte in plasma (Cmax) for empagliflozin

Time frame:
2 hours (h) before the administration in first subject and 0:20 h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, 72:00h after drug administration.
Reported as:
Geometric mean · nmol/L
Cmax for Empagliflozin
nmol/LEmpagliflozin 25 mg/ Linagliptin 5 mg (Reference;Fasted)Empagliflozin 25 mg/ Linagliptin 5 mg (Test;Fed)
Cmax for Empagliflozin1010 ± 27.1756 ± 27.3
Statistical analysis
  • Empagliflozin 25 mg/ Linagliptin 5 mg (Reference;Fasted) vs Empagliflozin 25 mg/ Linagliptin 5 mg (Test;Fed) · T/r ratio: 74.89 · 90% CI 66.27 to 84.64Standard Error of the mean is actually geometric Standard Error of the mean
PrimaryAUC 0-tz for Linagliptin

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration (AUC 0-tz) for linagliptin

Time frame:
2 hours (h) before the administration in first subject and 0:20 h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, 72:00h after drug administration.
Reported as:
Geometric mean · nmol∙h/L
AUC 0-tz for Linagliptin
nmol∙h/LEmpagliflozin 25 mg/ Linagliptin 5 mg (Reference;Fasted)Empagliflozin 25 mg/ Linagliptin 5 mg (Test;Fed)
AUC 0-tz for Linagliptin348 ± 15.4286 ± 20.5
Statistical analysis
  • Empagliflozin 25 mg/ Linagliptin 5 mg (Reference;Fasted) vs Empagliflozin 25 mg/ Linagliptin 5 mg (Test;Fed) · T/r ratio: 82.19 · 90% CI 78.38 to 86.18Standard Error of the mean is actually geometric Standard Error of the mean
PrimaryAUC 0-tz for Empagliflozin

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration (AUC 0-tz) for empagliflozin

Time frame:
2 hours (h) before the administration in first subject and 0:20 h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, 72:00h after drug administration.
Reported as:
Geometric mean · nmol∙h/L
AUC 0-tz for Empagliflozin
nmol∙h/LEmpagliflozin 25 mg/ Linagliptin 5 mg (Reference;Fasted)Empagliflozin 25 mg/ Linagliptin 5 mg (Test;Fed)
AUC 0-tz for Empagliflozin7210 ± 19.16200 ± 20.6
Statistical analysis
  • Empagliflozin 25 mg/ Linagliptin 5 mg (Reference;Fasted) vs Empagliflozin 25 mg/ Linagliptin 5 mg (Test;Fed) · T/r ratio: 85.99 · 90% CI 83.38 to 88.68Standard Error of the mean is actually geometric Standard Error of the mean
SecondaryAUC0-infinity for Linagliptin

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-infinity) for linagliptin

Time frame:
2 hours (h) before the administration in first subject and 0:20 h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, 72:00h after drug administration.
Reported as:
Geometric mean · nmol∙h/L
AUC0-infinity for Linagliptin
nmol∙h/LEmpagliflozin 25 mg/ Linagliptin 5 mg (Reference;Fasted)Empagliflozin 25 mg/ Linagliptin 5 mg (Test;Fed)
AUC0-infinity for Linagliptin597 ± 20.6526 ± 33.4
Statistical analysis
  • Empagliflozin 25 mg/ Linagliptin 5 mg (Reference;Fasted) vs Empagliflozin 25 mg/ Linagliptin 5 mg (Test;Fed) · T/r ratio: 88.13 · 90% CI 80.89 to 96.03Standard Error of the mean is actually geometric Standard Error of the mean
SecondaryAUC0-infinity for Empagliflozin

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-infinity) for empagliflozin.

Time frame:
2 hours (h) before the administration in first subject and 0:20 h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, 72:00h after drug administration.
Reported as:
Geometric mean · nmol∙h/L
AUC0-infinity for Empagliflozin
nmol∙h/LEmpagliflozin 25 mg/ Linagliptin 5 mg (Reference;Fasted)Empagliflozin 25 mg/ Linagliptin 5 mg (Test;Fed)
AUC0-infinity for Empagliflozin7270 ± 19.16280 ± 20.4
Statistical analysis
  • Empagliflozin 25 mg/ Linagliptin 5 mg (Reference;Fasted) vs Empagliflozin 25 mg/ Linagliptin 5 mg (Test;Fed) · T/r ratio: 86.33 · 90% CI 83.61 to 89.13Standard Error of the mean is actually geometric Standard Error of the mean
SecondaryAUC0-72 for Linagliptin

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 72 hours (AUC0-72) for linagliptin

Time frame:
2 hours (h) before the administration in first subject and 0:20 h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, 72:00h after drug administration.
Reported as:
Geometric mean · nmol∙h/L
AUC0-72 for Linagliptin
nmol∙h/LEmpagliflozin 25 mg/ Linagliptin 5 mg (Reference;Fasted)Empagliflozin 25 mg/ Linagliptin 5 mg (Test;Fed)
AUC0-72 for Linagliptin348 ± 15.4286 ± 20.5
Statistical analysis
  • Empagliflozin 25 mg/ Linagliptin 5 mg (Reference;Fasted) vs Empagliflozin 25 mg/ Linagliptin 5 mg (Test;Fed) · T/r ratio: 82.19 · 90% CI 78.38 to 86.18Standard Error of the mean is actually geometric Standard Error of the mean

Adverse events

Collected over From first drug administration until 7 days thereafter for each treatment arm, up to 8 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Empagliflozin 25 mg/ Linagliptin 5 mg (Reference;Fasted)—0/22 (0%)0/22 (0%)
Empagliflozin 25 mg/ Linagliptin 5 mg (Test;Fed)—0/22 (0%)0/22 (0%)

Baseline characteristics

Treated Set (TS): This analysis set included all 22 randomised subjects who were documented to have taken at least 1 dose of trial medication

Age, Continuous
Age, Continuous(Years)Empagliflozin 25 mg/ Linagliptin 5 mg (Sequence 1: Fed-Fasted)Empagliflozin 25 mg/ Linagliptin 5 mg (Sequence 2: Fasted-Fed)Total
Mean29.00 ± 8.8333.73 ± 9.5531.36 ± 9.30
Sex: Female, Male
Sex: Female, Male(Participants)Empagliflozin 25 mg/ Linagliptin 5 mg (Sequence 1: Fed-Fasted)Empagliflozin 25 mg/ Linagliptin 5 mg (Sequence 2: Fasted-Fed)Total
Female000
Male111122
08

Study locations

1 site
  • SOUSEIKAI Sumida Hospital
    Tokyo, Sumida-ku, 133-0004, Japan
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2016 to primary completion in Oct 2016, 2 months.

Results were first posted in Aug 2018, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2016
First posted
Jun 28, 2016
StartActual
Jul 15, 2016
Primary completionActual
Oct 5, 2016
CompletionActual
Oct 5, 2016
Results first posted
Aug 16, 2018
Last update
Aug 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02815644
Responsible party
Sponsor
First posted
Jun 28, 2016
Start date
Jul 15, 2016
Primary completion
Oct 5, 2016
Completion
Oct 5, 2016
Results posted
Aug 16, 2018
Last update
Aug 16, 2018

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Linagliptin

Start the discussion